Anti-Human HER2/neu Recombinant Antibody (ChA21) (CAT#: TAB-049CT)

Figure 1 SK-OV-3 invasion after incubation with chA21 for 24h(x400).

The invaded cells were counted on the underneath of ECM-coated Millicell membrane, chA21 (6μg/ml).

Gao, Y., Wu, Q., Wu, Z. S., Zhang, G. H., & Zhang, A. L. (2011). Effects of an engineered anti-HER2 antibody chA21 on invasion of human ovarian carcinoma cell in vitro. Chinese Journal of Cancer Research, 23(2), 147-152.

Figure 2 Growth inhibition on tumor xenografts by chA21.

ErbB2-positive expression on BT-474 and SKOV-3 tumor xenografts conWrmed by IHC method. Scale bar 500 μm.

Shen, G., Huang, H., Zhang, A., Zhao, T., Hu, S., Cheng, L., ... & Song, L. (2011). In vivo activity of novel anti-ErbB2 antibody chA21 alone and with Paclitaxel or Trastuzumab in breast and ovarian cancer xenograft models. Cancer immunology, immunotherapy, 60(3), 339-348.

Figure 3 Growth inhibition on tumor xenografts by chA21.

A dose-dependent response induced by chA21 on both BT-474 and SKOV-3 xenografts. chA21 was given i.v. twice a week for total 24 days at doses of 20, 30 and 40 mg/kg. *p < 0.01 compared with control. **p < 0.01 compared with 20 mg/kg chA21 group. Results are given as representative of two independent experiments.

Shen, G., Huang, H., Zhang, A., Zhao, T., Hu, S., Cheng, L., ... & Song, L. (2011). In vivo activity of novel anti-ErbB2 antibody chA21 alone and with Paclitaxel or Trastuzumab in breast and ovarian cancer xenograft models. Cancer immunology, immunotherapy, 60(3), 339-348.

Figure 4 Growth inhibition on tumor xenografts by chA21.

Dose-dependent down-regulation of ErbB2 receptor on both BT-474 and SKOV-3 xenografts by chA21. By the end of in vivo experiment, tumors were excised, lysed and subjected to western blots with specific antibodies against ErbB2 ECD (Ab-20) and GAPDH.

Shen, G., Huang, H., Zhang, A., Zhao, T., Hu, S., Cheng, L., ... & Song, L. (2011). In vivo activity of novel anti-ErbB2 antibody chA21 alone and with Paclitaxel or Trastuzumab in breast and ovarian cancer xenograft models. Cancer immunology, immunotherapy, 60(3), 339-348.

Figure 5 Increased number and activation of NK cells by chA21.

Nude mice bearing BT-474 xenografts were treated i.v. with indicated drug alone or combinations. At the end of in vivo experiment, the total numbers of NK cells (DX5+ CD3- cells) in peripheral blood and the percentages of NK cells in lymphocytes were determined by fow cytometry.

Shen, G., Huang, H., Zhang, A., Zhao, T., Hu, S., Cheng, L., ... & Song, L. (2011). In vivo activity of novel anti-ErbB2 antibody chA21 alone and with Paclitaxel or Trastuzumab in breast and ovarian cancer xenograft models. Cancer immunology, immunotherapy, 60(3), 339-348.

Figure 6 Increased number and activation of NK cells by chA21.

NK cells were evaluated for CD69 and NKG2D expression by fow cytometry. Histograms show CD69 and NKG2D expression on this cell subset, and mean fuorescence intensity (MFI) denotes expression level. Tra Trastuzumab, PTX Paclitaxel. Results were presented as the average ± SD. Similar results were obtained in mice bearing SKOV-3 xenografts.

Shen, G., Huang, H., Zhang, A., Zhao, T., Hu, S., Cheng, L., ... & Song, L. (2011). In vivo activity of novel anti-ErbB2 antibody chA21 alone and with Paclitaxel or Trastuzumab in breast and ovarian cancer xenograft models. Cancer immunology, immunotherapy, 60(3), 339-348.